$FSTX News
Last published 2y ago
- 2y agoPIRSTTOOFSTXAvacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of DirectorsGlobeNewswireAvacta Group plc Avacta Announces the Appointment of Darlene Deptula-Hicks as Non-Executive Director of the Board of Directors London, England; July 8, 2024; Avacta Group plc (AIM: AVCT), a life sciences company
- 2y agoIMCRIMTXPLXFSTXLevicept Appoints Eliot Forster as CEOGlobeNewswireLeadership Team Strengthened as Clinical Development of LEVI-04 a Novel Neurotrophin Modulator for Osteoarthritis and Chronic Pain Advances SANDWICH, United Kingdom, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Levicept Ltd, a
- 3y agoFSTXinvoX Pharma Completes Acquisition of F-star Therapeutics, Inc.Business WireinvoX Pharma Limited ("invoX"), a U.K.-based wholly-owned subsidiary of Sino Biopharmaceutical Limited ("Sino Biopharm") (HKEX 1177 HK) with an advancing pipeline of innovative products, today announces that it has
- 3y agoFSTXF-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX PharmaGlobeNewswireCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX) ("F-star" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing
- 3y agoFSTXinvoX Pharma and F-star Therapeutics issue Joint StatementGlobeNewswireLONDON, Jan. 26, 2023 (GLOBE NEWSWIRE) -- invoX Pharma ("invoX"), a wholly owned subsidiary of Sino Biopharmaceutical Limited ("Sino Biopharm") (HKEX 1177 HK), and F-star Therapeutics, Inc. ("F-star") (NASDAQ:FSTX),
- 3y agoFSTXF-star Therapeutics Presents Clinical Data on FS222, a CD137/PD-L1 Tetravalent Bispecific Antibody, at ESMO-IO 2022 CongressGlobeNewswireCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Dec. 06, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX) ("F-star" or the "Company"), a clinical-stage biopharmaceutical company pioneering bispecifics
- 4y agoFSTXF-star Therapeutics Announces Publication of Phase 1 Dose-Escalation Trial of FS118 in Patients with Advanced Cancer and PD-L1 Resistance in Clinical Cancer ResearchGlobeNewswire- FS118 is Well-Tolerated Across all Dose Levels with No Serious Adverse Events Related to FS118 Therapy - Novel mechanism showing Increased Peripheral Immune Cells and LAG-3 shedding - 54.8% Disease Control Rate in
- 4y agoFSTXF-star Therapeutics Reports Second Quarter 2022 Financial Results and Corporate HighlightsGlobeNewswirePreviously announced agreement for F-star Therapeutics to be acquired by invoX Pharma; transaction expected to close in the second half of 2022 License Agreement with Takeda to Develop and Commercialize a Novel Next-Generation Immuno-Oncology Bispecif
- 4y agoFSTXinvoX Pharma Extends Tender Offer to Acquire F-star Therapeutics, Inc.Business WireinvoX Pharma Limited ("invoX"), a wholly owned subsidiary of Sino Biopharmaceutical Limited ("Sino Biopharm") (HKEX 1177 HK), focused on research and development (R&D) and business development activities outside of China, and F-star Therapeutics, Inc. (
- 4y agoFSTXF-star Therapeutics Announces a License Agreement with Takeda for a Novel Next-Generation Immuno-oncology Bispecific AntibodyGlobeNewswireCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 20, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX) ("F-star"), operating through its subsidiary, F-star Therapeutics Ltd., a clinical-stage biopharmaceutical company pioneering
- 4y agoFSTXinvoX Pharma Commences Tender Offer for F-star Therapeutics, Inc.Business WireOn July 7, 2022, invoX Pharma Limited ("invoX"), a wholly owned subsidiary of Sino Biopharmaceutical Limited ("Sino Biopharm") (HKEX 1177 HK) commenced a cash tender offer for all of the issued and outstanding shares of common stock of F-star Therapeuti
- 4y agoADRAFSTXUSAKZENMoore Kuehn Encourages ZEN, FSTX, USAK, and ADRA Investors to Contact Law FirmGlobeNewswireNEW YORK, July 05, 2022 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair t
- 4y agoFSTXinvoX Pharma to Acquire F-star Therapeutics, Inc. a Pioneering Next Generation Bispecific Discovery Platform and Clinical ProgramsGlobeNewswireProposed ~US$161 million all-cash acquisition to accelerate invoX's strategy to build Sino Biopharm's International Biopharmaceutical R&D Platform outside of China, transforming the lives of patients worldwide The transaction demonstrates the strength
- 4y agoFSTXF-star Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswireFour Clinical Readouts Anticipated Throughout 2022 Mechanistic Data on FS118 Demonstrating Shedding Mechanism and LAG-3 Reduction Presented at the 2022 American Association for Cancer Research (AACR) Annual Meeting Company To Host Conference Call
- 4y agoFSTXF-star Therapeutics to Announce First Quarter Results and Host Conference Call on Tuesday, May 10th, 2022GlobeNewswireCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of pati
- 4y agoFSTXF-star Therapeutics Presents a Novel LAG-3 Reduction and Shedding Mechanism with FS118 at AACR 2022GlobeNewswireCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of pa
- 4y agoFSTXF-star Therapeutics Reports Full-Year 2021 Financial Results and Provides Corporate UpdateGlobeNewswireMultiple Clinical Program Updates Expected in 2022 Continued Expansion of Leading Bispecific Antibody IP Estate Two New Significant Partnerships with Janssen and AstraZeneca Company to Host Conference Call Today at 9 a.m. EDT CAMBRIDGE, Unite
- 4y agoFSTXF-star Therapeutics to Present at the 32nd Annual Oppenheimer Healthcare ConferenceGlobeNewswireCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of pa
- 4y agoFSTXF-star Therapeutics to Host Fourth Quarter and Full-Year 2021 Financial Results Conference Call on March 14, 2022GlobeNewswireCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of pa
- 4y agoFSTXF-star Therapeutics Appoints James Sandy as Chief Development OfficerGlobeNewswireCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of pa
- 4y agoFSTXF-star Announces Issuance of U.S. Patent Protecting FS118, a Bispecific Antibody Targeting PD-L1 and LAG-3GlobeNewswireProvides U.S. Patent Protection to at least August 2038 Expands Patent Protection for FS118 Composition of Matter beyond Europe CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 20, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:F
- 4y agoFSTXF-star Therapeutics to Participate in Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next-generation bispecific immunotherapies to transform the li
- 4y agoFSTXF-star Therapeutics Announces Merck KGaA, Darmstadt, Germany Exercises a Fourth Licensing Option in Immuno-Oncology CollaborationGlobeNewswireCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the li
- 4y agoFSTXF-star Therapeutics to Present FS222 Trial-in-Progress Update at ESMO Immuno-Oncology Congress 2021GlobeNewswireCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Dec. 07, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the li
- 4y agoFSTXF-star Therapeutics to Host Virtual R&D Day on December 6, 2021GlobeNewswireCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 29, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the li
- 5y agoFSTXF-star Therapeutics to Present at The Society for Immunotherapy of Cancer (SITC) 2021 ConferenceGlobeNewswireDr. Michelle Morrow to present on F-star's Proprietary Bispecific Platform including FS118, our LAG-3/PD-L1 Bispecific Poster Presentation of Preclinical Data Demonstrates Potential for F-star's FS120 First-in-Class OX40/CD137 Tetravalent Dual T Cel
- 5y agoFSTXAerami Therapeutics Appoints Darlene Deptula-Hicks to its Board of DirectorsGlobeNewswireDURHAM, N.C., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc., a leader in the field of developing inhaled therapies to treat severe respiratory and chronic diseases, today announced the appointment of Darlene Deptula–Hicks, Chief Financ
- 5y agoFSTXF-star Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswireCompany to Host Conference Call Today at 9 a.m. EST CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next
- 5y agoFSTXF-star Therapeutics to Announce Third Quarter Results and Host Conference Call on November 10, 2021GlobeNewswireCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Nov. 01, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of pat
- 5y agoBVNCIDMFSTXOYST+1Thinking about buying stock in Oyster Point Pharma, Tegna, Compania de Minas Buenaventura, F-Star Therapeutics, or Cinedigm?PR NewswireNEW YORK, Oct. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OYST, TGNA, BVN, FSTX, and CIDM. T
- 5y agoFSTXF-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody TherapeuticsGlobeNewswireCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Oct. 20, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Ltd. (NASDAQ:FSTX) ("F-star" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies t
- 5y agoFSTXPIRSTTOOAbcuro Appoints Darlene Deptula-Hicks to its Board of DirectorsBusiness WireAbcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the appointment of Darlene Deptula-Hicks as a member of the company's Bo
- 5y agoFSTXF-star Therapeutics to Present FS120 Phase 1 Trial-in-Progress Update at ESMO 2021GlobeNewswireCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Sept. 16, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the
- 5y agoFSTXF-star Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment ConferenceGlobeNewswireCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the
- 5y agoFSTXF-star Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswireCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 12, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the l
- 5y agoFSTXF-star Therapeutics is Granted Composition of Matter Patent for its Novel Second Generation STING Agonist, SB 11285GlobeNewswirePatent protection in U.S. runs through 2037 CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 10, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX) ("F-star" or the "Company"), a clinical-stage biopharmaceutical company dedicated
- 5y agoFSTXF-star Therapeutics to Announce Second Quarter Results and Host Conference Call on August 12, 2021GlobeNewswireCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 02, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of pat
- 5y agoFSTXF-star Therapeutics Provides Interim Update on SB 11285 First-In-Human Dose-Escalation Study in Patients with Advanced Solid TumorsGlobeNewswireCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX) ("F-star" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies t
- 5y agoFSTXF-star Therapeutics to Present at Upcoming Investor ConferencesGlobeNewswireCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 09, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of pati
- 5y agoAZNFSTXF-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING InhibitorsGlobeNewswireCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX) ("F-star" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immuno
- 5y agoFSTXIONTAS Collaboration With F-star Enters Oncology Phase 1 Clinical TrialBusiness WireIONTAS Limited (IONTAS), a leader in the discovery and optimization of fully human antibodies, today announces that F-star Therapeutics, Inc. (NASDAQ:FSTX), has dosed the first patients in a Phase 1 clinical trial, with FS222, a CD137/PD-L1 bispecific a
- 5y agoFSTXInivata Announces Collaboration with F-star Therapeutics for the use of RaDaRTM AssayGlobeNewswireInivata Announces Collaboration with F-star Therapeutics for the use of RaDaRTM Assay RaDaR ctDNA liquid biopsy to monitor response of late-stage solid tumors to treatment Research Triangle Park, NC, USA and Cambridge, UK, 25 May 2021 -- Inivat
- 5y agoFSTXF-star Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate UpdateGlobeNewswireCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 17, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the li
- 5y agoFSTXF-star Therapeutics Inc to Host Earnings CallACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 17, 2021 / F-star Therapeutics Inc (NASDAQ:FSTX) will be discussing their earnings results in their 2021 First Quarter Earnings call to be held on May 17, 2021 at 9:00 AM Eastern Time. To listen to the event live or acces
- 5y agoFSTXF-star Therapeutics to Announce First Quarter Results and Corporate Update Call on May 17, 2021GlobeNewswireCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 10, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to transform the lives of pati
- 5y agoFSTXF-star Therapeutics, Inc. Announces Pricing of $65 Million Public Offering of Common StockGlobeNewswireCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 07, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX) (the "Company" or "F-star"), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to
- 5y agoFSTXF-star Therapeutics, Inc. Announces Proposed Public Offering of Common StockGlobeNewswireCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., May 06, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ:FSTX) (the "Company" or "F-star"), a clinical-stage biopharmaceutical company dedicated to developing next generation immunotherapies to
- 5y agoFSTXStudy Published in Nature Shows F-Star's STING Agonist SB 11285 Enhances Preclinical Efficacy of Radiation TherapyGlobeNewswireSB 11285 in Combination with Radiation is More Effective than Either as Monotherapy in a Murine Tumor Model SB 11285 is a Second Generation STING Agonist Delivered Intravenously CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 19, 2021 (GLOB
- 5y agoFSTXF-star Therapeutics Shows Differentiation of FS222 in 2021 AACR PosterGlobeNewswireCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 10, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...
- 5y agoFSTXF-star Therapeutics Announces Third Option Exercised by Merck KGaA, Darmstadt, Germany in Immuno-Oncology CollaborationGlobeNewswireCAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 01, 2021 (GLOBE NEWSWIRE) -- F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next...